| 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 金嗓子控股集團有限公司 | | 股份代號 | 06896 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日的年度末期股息 | | 公告日期 | 2026年3月27日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.34 HKD | | 股東批准日期 | 有待公佈 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.34 HKD | | 匯率 | 1 HKD : 1 HKD | | 除淨日 | 有待公佈 ...

Financial Performance - The group's revenue decreased by approximately RMB 241.7 million or 20.4% to about RMB 943.3 million for the year ended December 31, 2025[3]. - Gross profit fell by approximately RMB 177.2 million or 19.8% to about RMB 717.0 million compared to the year ended December 31, 2024[3]. - EBITDA decreased by approximately RMB 112.0 million or 22.9% to about RMB 377.1 million for the year ended December 31, 2025[3]. - Profit attributable to equity holders decreased by approximately RMB 67.4 million or 21.2% to about RMB 251.2 million compared to the previous year[3]. - Total comprehensive income for the year was RMB 249.0 million, down from RMB 319.4 million in the previous year[5]. - The company's revenue for the year ending December 31, 2025, was approximately RMB 943.3 million, a decrease of about RMB 241.7 million or 20.4% compared to RMB 1,185.0 million for the year ending December 31, 2024, primarily due to adjustments in marketing strategies leading to reduced procurement by distributors[49]. - Net profit for the year ending December 31, 2025, was approximately RMB 251.2 million, a decrease of RMB 67.4 million or 21.2% compared to RMB 318.6 million for the year ending December 31, 2024[62]. Assets and Liabilities - Non-current assets increased to RMB 513.4 million from RMB 495.0 million in the previous year[6]. - Current assets totaled RMB 1,775.7 million, slightly up from RMB 1,756.2 million in 2024[6]. - The net asset value decreased to RMB 1,376.7 million from RMB 1,466.3 million in the previous year[7]. - Total bank loans and other borrowings amounted to RMB 584.266 million as of December 31, 2025, compared to RMB 426.916 million as of December 31, 2024[25]. - The current ratio decreased from 2.5 on December 31, 2024, to 2.2 on December 31, 2025, with net current assets of approximately RMB 957.4 million[63]. - Total interest-bearing bank and other borrowings increased from approximately RMB 426.9 million as of December 31, 2024, to approximately RMB 584.2 million as of December 31, 2025, an increase of RMB 157.3 million[64]. - The debt-to-equity ratio increased from approximately 29.1% on December 31, 2024, to approximately 42.4% on December 31, 2025[66]. Revenue Sources - Total revenue from external customers decreased to RMB 943,258,000 in 2025 from RMB 1,185,004,000 in 2024, representing a decline of approximately 20.4%[12]. - Revenue from a major customer (Customer A) decreased to RMB 137,410,000 in 2025 from RMB 148,375,000 in 2024, a decline of about 7.9%[13]. - Revenue from the sales of Jin Sang Zi throat lozenges (OTC) was approximately RMB 873.0 million, down RMB 222.3 million or 20.3% from RMB 1,095.3 million in the previous year, attributed to a decline in sales volume[49]. - Revenue from the sales of Jin Sang Zi throat treasure series products was approximately RMB 65.3 million, a decrease of RMB 21.4 million or 24.7% compared to RMB 86.7 million in the previous year, also due to a decline in sales volume[49]. - The flagship product, Jin Sangzi throat lozenges (OTC), accounted for approximately 92.6% of the total revenue for the year ending December 31, 2025[30]. - The sales of other products accounted for approximately 0.5% of the total revenue for the year ending December 31, 2025[33]. Expenses and Costs - The pre-tax profit before deductions was impacted by a decrease in the cost of sales to RMB 226,248,000 in 2025 from RMB 290,820,000 in 2024, a reduction of approximately 22.2%[17]. - Total financial costs decreased slightly to RMB 14,384,000 in 2025 from RMB 15,363,000 in 2024, a decline of about 6.4%[18]. - Income tax expense for the year was RMB 77,658,000 in 2025, down from RMB 118,647,000 in 2024, a decrease of approximately 34.5%[19]. - Selling and distribution expenses were approximately RMB 313.5 million for the year ending December 31, 2025, down RMB 42.4 million or 11.9% from approximately RMB 355.9 million for the year ending December 31, 2024[57]. - Administrative expenses decreased from approximately RMB 117.1 million for the year ending December 31, 2024, to approximately RMB 96.8 million for the year ending December 31, 2025, a reduction of RMB 20.3 million or 17.3%[58]. - The sales cost decreased from approximately RMB 290.8 million for the year ending December 31, 2024, to approximately RMB 226.2 million for the year ending December 31, 2025, primarily due to a reduction in sales volume of Jin Sang Zi throat lozenges (OTC)[52]. Product Development and Market Strategy - The company is focusing on expanding its product range and enhancing organizational capabilities to strengthen its market position in the throat lozenge market and increase its market share in China's pharmaceutical and food sectors[45]. - The company plans to maintain and promote its "Jin Sang Zi" brand to enhance brand recognition and image in China, aiming to make it a household name for effective and safe throat lozenge products[47]. - The company is developing a new product line, Jin Sang Zi propolis soothing spray, designed for throat discomfort, which will be primarily sold through online platforms[44]. - The company is investing in the development of probiotics with proprietary strains and advanced technologies, aiming to capture the growing health-conscious consumer market in China[43]. - The company has diversified its product offerings with the Jin Sangzi throat treasure series, which includes sugar-free options to cater to different consumer preferences[31]. - The new product, Jin Sangzi Propolis Soothing Spray, was launched in 2025, targeting throat discomfort with herbal ingredients and is primarily sold online[33]. Digital Presence and Expansion - The company has established an online flagship store for Jin Sangzi throat treasure on Tmall, enhancing its digital presence and product accessibility[32]. - The company continues to adapt to the online consumption trend, having established flagship stores on platforms like Tmall and WeChat, with plans for further expansion in online sales channels by 2025[46]. - The company has expanded its international presence, exporting products to over 60 countries, with new markets including South Korea, Peru, Ecuador, and Uzbekistan in 2025[37]. - The distribution network covers all provinces and municipalities in China, with a focus on enhancing cooperation with key distributors and online pharmacies[38]. - The company has signed agency agreements with all 10 ASEAN countries, successfully exporting products to nine of them[39]. - The company has established promotional agreements with 11 promoters to leverage local market knowledge and enhance product visibility[40]. Corporate Governance and Management - The board proposed a final dividend of HKD 0.34 per share, subject to approval at the upcoming annual general meeting[3]. - The company secretary, Ms. Li, has resigned effective March 27, 2026, with no disagreements reported with the board[86]. - Ms. Qu has been appointed as the new company secretary, effective March 27, 2026, bringing over ten years of experience in corporate secretarial services[87]. - The board expresses gratitude to Ms. Li for her contributions during her tenure and welcomes Ms. Qu to her new role[88]. Future Outlook and Investments - The group plans to continue strengthening its leading position in the throat lozenge market and expand its market share in China's pharmaceutical and food sectors in 2026[74]. - The group has committed to invest approximately RMB 154 million in the construction of a new pharmaceutical production and R&D base in Liuzhou, Guangxi, by December 31, 2025[72]. - The second phase of the new base, covering 50,000 square meters, is under construction and will include a health industry production facility and R&D center, expected to enhance innovation in health products[48]. - The group is actively enhancing its production capacity, expanding its product portfolio, and strengthening R&D capabilities to promote synergy among different product segments[74]. - The unutilized proceeds from the initial public offering are expected to be fully utilized by 2028[77]. - The financial data presented does not constitute audited accounts for the year ending December 31, 2025, but is extracted from the consolidated financial statements reviewed by the auditor, Ernst & Young[84]. - The audited annual results and the 2025 annual report will be published on the Stock Exchange and the company's website in due course[85].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 承董事會命 金嗓子控股集團有限公司 主席 江佩珍 中國廣西 2026年3月17日 於本公告日期，董事會成員包括非執行董事江佩珍女士；執行董事曾勇先生、黃建平先 生、曾克雄先生及何錦強先生；及獨立非執行董事李驊先生、朱頡榕先生、程益群先生 及覃解生先生。 6896 董事會會議通告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.43條而作出。 金嗓子控股集團有限公司（「本公司」）董事會（「董事會」）謹此宣佈，董事會會議將於2026 年3月27日（星期五）舉行，藉以（其中包括）審議及批准本公司及其附屬公司截至2025年12 月31日止年度業績及其發佈，並考慮宣派及派發末期股息（如有）。 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED ...

6896 盈利預警 本公告由金嗓子控股集團有限公司（「本公司」，連同其附屬公司稱為「本集團」）根據香港 法例第571章證券及期貨條例第XIVA部項下之內幕消息條文及香港聯合交易所有限公司 證券上市規則第13.09條而作出。 本公司董事會（「董事會」）謹此宣佈，根據初步評估本集團截至2025年12月31日止年度之 未經審核綜合管理賬目及董事會目前可得資料，於截至2025年12月31日止年度，本集團 預期，營業收入及溢利與2024年同期比較，下降範圍在20%-25%之間。下降主要由於 2025年全年行業形勢的改變，本集團產品營銷策略調整，使得客戶經銷商2025年全年減 少了採購，導致本集團2025年全年的銷售額及溢利有所下降。 - 1 - 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 GOLDEN THROAT HOLDINGS GROUP COMPANY LIMITED 本公司現正落實本集團截至2025年12月31日止年度之全年綜合財務業績。本公告所 ...

截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 金嗓子控股集團有限公司 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06896 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,00 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 金嗓子控股集團有限公司 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06896 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 金嗓子控股集團有限公司 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06896 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,0 ...

Golden Throat Holdings Group Company Limited 金嗓子控股集團有限公司 董事會提名委員會的 職權範圍 （於2015年2月13日採納並於2025年12月24日修訂） - 1 - 定義 於本職權範圍內，除文義另有所指外，下列詞彙具有以下涵義： 1. 設立 - 2 - 「董事會」 指 公司董事會； 「委員會」 指 公司董事會之提名委員會； 「公司」 指 金嗓子控股集團有限公司； 「董事」 指 公司所有的董事，且「董事」指任何一位董事； 「獨立非執行董事」 指 符合上市規則獨立性規定的非執行董事，且「獨立非執 行董事」指任何一位獨立非執行董事；及 「上市規則」 指 香港聯合交易所有限公司證券上市規則。 2.1 委員會應至少由三名董事組成，且獨立非執行董事應佔大多數，並且應有至少一名 不同性別的董事。 2.2 委員會主席應由董事會任命，並應由董事會主席或一位獨立非執行董事擔任。 2.3 委員會秘書應為公司秘書，或委員會不時指派的任何人員。 2.4 委員會成員的任期應由董事會決定，且輪流退任和連任選舉應符合公司章程的規 定。 3.2 委員會主席可酌情召集會議，但無論如何，於每年應 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 金嗓子控股集團有限公司 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06896 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50, ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06896 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 739,302,000 | | 0 | | 739,302,000 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 739,302,000 | | 0 | | 739,302,000 | 致：香港交易及結算所有限公司 公司名稱: 金嗓子控股集團有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | ...